● Recruiting

A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Condition: Crohn Disease · Sponsor: Anterogen Co., Ltd.

PhaseN/A

Planned participants9

Who can joinAll sexes, 18 Years to 65 Years

Healthy volunteersNo

About this study

This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.

This description comes directly from the study's public registry record.

Talk to the study team

Jae Hee Cheon, Ph D · GENIUSHEE@yuhs.ac

Always discuss trial participation with your own doctor first.

Locations (2)

Seoul National University Hospital	Seoul, South Korea	Recruiting
Severance Hospital	Seoul, South Korea	Completed

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03183661